ACP
BLCM

Acuta Capital Partners’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Acuta Capital Partners’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,399
Closed -$1.02M – 62
2015
Q1 		$1.02M Sell
4,399
-176
-4% -$42.6K 0.86% 30
2014
Q4 		$1.05M Buy
+4,575
New +$981K 0.71% 41

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's BLCM Position: Q2 2015 in Review

Acuta Capital Partners sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2015, closing a stake of 4,399 shares — an estimated $1.02M sold.

Acuta Capital Partners first reported a position in BLCM in Q4 2014 and held it in 2 quarters. The position peaked at $1.05M in Q4 2014. 81 funds tracked by Wall St. Rank hold BLCM as of Q2 2015.

  • Acuta Capital Partners reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 4,399 Bellicum Pharmaceuticals, Inc. shares in Q2 2015, an estimated $1.02M.
  • Acuta Capital Partners first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
  • Acuta Capital Partners's Bellicum Pharmaceuticals, Inc. position peaked at $1.05M in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2015.

Based on Acuta Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.